Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant followed by everolimus + exemestane versus the reverse sequence in HR-positive/HER2-negative advanced breast cancer
2014-004035-38Phase 3Completed
- Sponsor
- Consorzio Oncotech
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fulvestrant, everolimus and exemestane in breast cancer (2 arms), sponsored by Consorzio Oncotech. Primary endpoints: First treatment progression-free survival and Total progression-free survival. Started Feb 2016; status: completed.
02
Drugs
fulvestranteverolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-004035-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004035-38.